In vivo studies could not confirm in vitro prophylactic synergism between Moringa essential oil and Lactobacillus reuteri (MT180537) / Estudos in vivo não puderam confirmar o sinergismo profilático in vitro entre o óleo essencial de Moringa e Lactobacillus reuteri (MT180537)

Aerobic vaginitis (AV) is a recently defined vaginal recurring infection, which is treated with antibiotics. However, excessive and prolonged use of antibiotics disrupts healthy vaginal microflora and leads to the emergence of antibiotic resistance among pathogens. This situation has directed researchers to explore alternative antimicrobials. The current study describes in vitro and in vivo antimicrobial efficacy and pharmaceutical interactions between plant essential oils (EOs) and five lactic acid bacteria (LABs), isolated from the healthy vagina, against E. faecalis, one of the major etiological agents of AV. In vitro experiments confirm good antimicrobial activity of both plant EOs and cell free supernatant (CFS) from LABs. Based on high antimicrobial efficacy, Moringa essential oil (MO) was selected to determine its nature of interaction with CFS of five LAB strains. Synergism was recorded between MO and CFS of L. reuteri (MT180537). To validate in vitro findings, prophylactic responses of individual and synergistic application of MO and L. reuteri (MT180537) were evaluated in an E. faecalis (MW051601) induced AV murine model. The prophylactic efficacy was evidenced by a reduction in intensity of clinical symptoms, E. faecalis (MW051601) count per vaginal tissue along with a reduction in AV associated changes in histological markers of infection in animals receiving Moringa essential oil and L. reuteri (MT180537) alone or in combination. However, significant synergism between Moringa essential oil and L. reuteri (MT180537) could not be observed. Our data confirms the importance of in vivo experiments in deducing pharmacological interactions.

Vaginite aeróbica (VA) é uma infecção vaginal recorrente definida recentemente, que é tratada com antibióticos. No entanto, o uso excessivo e prolongado de antibióticos perturba a microflora vaginal saudável e leva ao surgimento de resistência aos antibióticos entre os patógenos. Esta situação levou os pesquisadores a explorar antimicrobianos alternativos. O presente estudo descreve a eficácia antimicrobiana in vitro e in vivo e as interações farmacêuticas entre óleos essenciais vegetais (OE) e cinco bactérias lácticas (BAL), isoladas de vagina sã, contra E. faecalis, um dos principais agentes etiológicos da AV. Os experimentos in vitro confirmam a boa atividade antimicrobiana de ambos os EOs de plantas e sobrenadante livre de células (CFS) de LABs. Com base na alta eficácia antimicrobiana, o óleo essencial de Moringa (MO) foi selecionado para determinar sua natureza de interação com o sobrenadante livre de células (CFS) de cinco cepas de LAB. Sinergismo foi registrado entre MO e CFS de L. reuteri (MT180537). Para validar os resultados in vitro, as respostas profiláticas da aplicação individual e sinérgica de MO e L. reuteri (MT180537) foram avaliadas em um modelo murino AV induzido por E. faecalis (MW051601). A eficácia profilática foi evidenciada por uma redução na intensidade dos sintomas clínicos, contagem de E. faecalis (MW051601) por tecido vaginal, juntamente com uma redução nas alterações associadas a AV nos marcadores histológicos de infecção em animais que receberam óleo essencial de Moringa e L. reuteri (MT180537) sozinho ou em combinação. No entanto, não foi possível observar sinergismo significativo entre o óleo essencial de Moringa e L. reuteri (MT180537). Nossos dados confirmam a importância dos experimentos in vivo na dedução de interações farmacológicas.

Comparison of the effect of miconazole and clotrimazole in the treatment of vulvovaginal candidiasis among women seen in a tertiary medical center from 2016 to 2020 / Philippine Journal of Obstetrics and Gynecology

Background@#Vulvovaginal Candidiasis (VVC) is one of the frequent infections of the female genital tract and is the second most common cause of vaginal infections after bacterial vaginosis. According to the Centers for Disease Control and Prevention, azoles are the first‑line treatment for VVC. Among the azoles available in the Philippines, only miconazole and clotrimazole are recommended for both pregnant and non‑pregnant women.@*Objective@#Compare the effect of miconazole versus clotrimazole in the treatment of vulvovaginal candidiasis among patients seen at the out‑patient department in a tertiary hospital@*Materials and Methods@#This involved review of the records of patients diagnosed with VVC in a tertiary medical center from 2016 to 2020. All records of women, pregnant and non‑pregnant, wherein single‑dose 1200 mg miconazole or 6‑day 100 mg clotrimazole given vaginally were included@*Results@#Eleven out of the 316 records (3.46%) remained symptomatic after treatment, about 18.1% (2/161) from those who used miconazole and 81.8% (9/155) from those treated with clotrimazole (p 0.027). In terms of failure rate, for miconazole it was 1.2% (2/161), whereas for clotrimazole it was 5.8% (9/155). None of the charts were found to have recorded adverse reaction to the given treatment@*Conclusion@#Single‑dose miconazole intravaginal regimen has a higher clinical cure rate than the 6‑day clotrimazole intravaginal treatment. Thereby, single‑dose intravaginal miconazole has the potential to improve patient compliance and treatment outcome at a lower cost

Agents causing genital infections in routine cytological tests: frequency and characteristics of Papanicolaou smears / Agentes causadores de infecções genitais em exames citológicos de rotina: frequência e características dos esfregaços de papanicolaou

Urinary tract infections are responsible for most human infections, these are caused by bacteria, fungi, protozoa and associated microorganisms. The goal of this study was to determine the rate of vaginal infection-causing agents in routine cytological exams and also to evaluate the characteristics of positive tested Pap smears. A retrospective documental with descriptive aspect research was performed in a Clinical Pathology laboratory from Maceió-AL. The results of the Pap smears exams for Trichomonas vaginalis, Gardnerella vaginalis, Candida spp and HPV were arranged in a database as well as other data such as bacterial, protozoan, fungal and viral coinfections. The sample was composed by 18.645 women who have undergone Pap smear exams from 2013 to 2017. Of these analyzed exams, 27.4% in 2013, 10.9% in 2014, 10.6% in 2015, 15.2% in 2016 and 13.67% in 2017 were within normal range, however more than half of these exams presented some infections caused by unspecific or microbiological agents. By analyzing all the reports, 4.073 (21.84%) presented inflammations caused by some species of infectious agent with the following rate order: G. vaginalis and T. vaginalis. Furthermore, it was possible to confirm high rates of coinfection by and Candida spp. The rate of genital infections in this study highlights that there is a public health matter that must be controlled, which points a greater need for monitoring, guidance and actions towards greater awareness in order to prevent these problems.

Infecções do trato urinário são responsáveis pela maior parte das infecções humanas, sendo causadas por bactérias, fungos, protozoários, e por microrganismos associados. O objetivo deste trabalho foi determinar a frequência de agentes causadores de infecções vaginais nos exames citológicos de rotina, bem como avaliar as características dos esfregaços positivos. Foi realizada uma pesquisa do tipo documental retrospectiva de aspecto descritivo, com abordagem quantitativa, em um Laboratório de Patologia Clínica de Maceió-AL. Nesse sentido, os resultados dos exames colpocitológicos para Trichomonas vaginalis, Gardnerella vaginalis, Candida spp e HPV foram organizados em um banco de dados, contendo os resultados para estes agentes, bem como a coinfecção bacteriana, protozoária, fúngica e viral. A amostra foi composta por 18.645 mulheres que realizaram exame colpocitológico, no período de 2013 a 2017. Destes exames analisados 27,4% em 2013, 10,9% em 2014, 10,6% em 2015, 15,2% em 2016 e 13,67% em 2017, estavam dentro do limite da normalidade, porém mais que a metade desses exames analisados apresentou algumas infecções causadas por agentes inespecíficos ou microbiológicos. Do total de laudos analisados, 4.073 (21,84%), apresentaram inflamações causadas por algum tipo de agente infeccioso, com a seguinte ordem de frequência: G. vaginalis, e T. vaginalis. Além disto, foi possível confirmar a elevada frequência de coinfecção entre G. vaginalis e Candida spp. Os índices de infecções genitais nesse trabalho mostram que há um problema de saúde pública que deve ser controlado, apontando uma necessidade maior de acompanhamento, orientações e de ações para uma maior conscientização para prevenir esses problemas.

Factores asociados a Chlamydia trachomatis en mujeres con vaginitis atendidas en atención primaria en salud / Factors associated with Chlamydia trachomatis in women with vaginitis attending in primary health care

INTRODUCCIÓN: Chlamydia trachomatis es reconocida como el agente causal de una de las infecciones de transmisión sexual (ITS) más común y curable. En mujeres, puede ser gatillante de enfermedad inflamatoria pélvica, un factor de riesgo para infertilidad o adquisición de otras ITS. OBJETIVO: Determinar C. trachomatis en mujeres con diagnóstico clínico de vaginitis asociando factores sociodemográficos, sexuales, clínicos y microbiota vaginal. PACIENTES Y MÉTODOS: Participaron 121 mujeres voluntarias > 18 años, con diagnóstico clínico de vaginitis y descarga vaginal anormal, atendidas en servicios de atención primaria en salud (APS) en Temuco-Chile. Se tomó muestra de flujo vaginal, determinándose C. trachomatis por una reacción de polimerasa en cadena convencional y microbiota vaginal por tinción de Gram. Se colectaron datos clínicos, sociodemográficos y sexuales mediante encuesta. RESULTADOS: Rango de edad 18-61 años. La frecuencia de C. trachomatis fue 14,9%. Se asoció C. trachomatis a mayor número de parejas sexuales en los últimos 5 años (p = 0,001), relaciones sexuales oral más anal (p = 0,055) y juguetes sexuales (p = 0,027). Asociación no significativa hubo con vaginosis bacteriana 31,2% (p = 0,091) e inicio de la actividad sexual < 18 años 20,6% (p = 0,07). CONCLUSIONES: Sería beneficioso incorporar en la semiología ginecológica de las mujeres atendidas en servicios de APS, los factores encontrados como favorecedores de infección por C. trachomatis, pues ello podría ayudar al manejo de esta ITS.

BACKGROUND: Chlamydia trachomatis is recognized as the causative agent of one of the most common and curable sexually transmitted infections (STIs). In women, it can be a trigger for pelvic inflammatory disease, a risk factor for infertility or acquisition of other STIs. AIM: To determine CT in women with vaginitis and associate it with sociodemographic, sexual, clinical, and vaginal microbiota factors. Methods: 121 female volunteers > 18 years of age, with a clinical diagnosis of vaginitis and abnormal vaginal discharge, attending in primary health care services (PHC) in Temuco-Chile were recluted. A vaginal discharge sample was taken, determining C. trachomatis by polymerase chain reaction and vaginal microbiota by Gram stain. Clinical, sociodemographic and sexual data were collected by survey. RESULTS: Age range was 18-61 years. The frequency of C. trachomatis was 14.9%. C. trachomatis was associated with a higher number of sexual partners in the last 5 years (p = 0.001), oral plus anal sex (p = 0.055) and sex toys (p = 0.027); there was a non-significant association with bacterial vaginosis 31.2% (p = 0.091) and initiation of sexual activity < 18 years 20.6% (p = 0.07). CONCLUSIONS: It would be beneficial to incorporate in the gynecological semiology of the women attended in PHC services, the factors found to favor C. trachomatis infection, as this could help the management of this STI.

Protocolo Brasileiro para Infecções Sexualmente Transmissíveis 2020: infecções que causam corrimento vaginal / Brazilian Protocol for Sexually Transmitted Infections 2020: infections causing vaginal discharge / Protocolo Brasileño para Infecciones de Transmisión Sexual 2020: infecciones que causan flujo vaginal

O tema corrimento vaginal é um dos capítulos que compõem o Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis, publicado pelo Ministério da Saúde do Brasil em 2020. Tal documento foi elaborado com base em evidências científicas e validado em discussões com especialistas. Neste artigo, são apresentados aspectos epidemiológicos e clínicos relacionados às situações de corrimento vaginal, bem como orientações aos gestores e profissionais de saúde na triagem, diagnóstico e tratamento desses agravos, que constituem uma das principais queixas entre mulheres que procuram serviços de saúde e que podem ser causados por fatores infecciosos ou não infecciosos. Além disso, são apresentadas informações sobre estratégias para as ações de vigilância, prevenção e controle, a fim de promover o conhecimento do problema e a oferta de assistência de qualidade e tratamento efetivo.

The topic of vaginal discharge is one of the chapters of the Clinical Protocol and Therapeutic Guidelines for Comprehensive Care for People with Sexually Transmitted Infections, published by the Brazilian Ministry of Health in 2020. The chapter has been developed based on scientific evidence and validated in discussions with specialists. This article presents epidemiological and clinical aspects related to vaginal discharge conditions, as well as guidelines for health service managers and health professionals about screening, diagnosing and treating these conditions, which are one of the main complaints among women seeking health services, and which may be caused by infectious or non-infectious factors. In addition, information is presented on strategies for surveillance, prevention and control actions, in order to promote knowledge of the problem and provision of quality care and effective treatment.

El tema del flujo vaginal es uno de los capítulos del Protocolo Clínico y Directrices Terapéuticas para la Atención Integral a las Personas con Infecciones de Transmisión Sexual, publicado por el Ministerio de Salud de Brasil en 2020. El documento fue desarrollado en base a evidencia científica y validado en discusiones con especialistas. En este artículo se presentan aspectos epidemiológicos y clínicos relacionados a las situaciones de flujo vaginal, así como pautas para gestores y profesionales de la salud en el cribado, diagnóstico y tratamiento de esas complicaciones, que son una de las principales quejas entre las mujeres que buscan servicios de salud y que pueden ser causadas por factores infecciosos o no infecciosos. Además, se presenta información sobre estrategias para acciones de vigilancia, prevención y control, con el fin de promover la comprensión del problema y la oferta de asistencia de calidad y tratamiento eficaz.

Vaginitis citolítica y los errores terapéuticos: Cómo hacer un diagnóstico y tratamiento diferenciado de la vaginitis candidiásica recurrente / Cytolystic vaginitis. How to make a diagnosis and differentiated treatment from recurrent caginitis vaginitis

Introducción: La vaginitis citolítica (VC) se refiere a la lisis de las células del epitelio intermedio de la vagina causado por un aumento de lactobacilos que provocan acidificación extrema de la vagina. Los síntomas pueden llevar a confundir su diagnóstico con vulvovaginitis candidiásica (VVC), por lo que puede ser tratada de manera errónea con antimicóticos sin responder al tratamiento. Objetivo: Realizar una revisión bibliográfica sobre el diagnóstico y tratamiento diferencial de la VC. Métodos: Se realizó una búsqueda bibliográfica en varias bases de datos: Academic Google, Scopus, PubMed, LILACS, ClinicalKey utilizando los términos MeSH y DeCS: "vaginitis citolítica", "cytolitic vaginitis", "vulvovaginitis candidiásica", "vaginitis recurrente". Resultados: Se identificaron 42 artículos de los cuales se seleccionó 34 para la presente revisión. Discusión: En la VC a través de estudios complementarios se puede identificar abundantes lactobacilos, especialmente L. crispatus y pH vaginal inferior a lo normal. El examen lipídico de secreciones vaginales, sugiere la existencia de niveles elevados de lípidos relacionados con apoptosis celular, estrés oxidativo y sobrecrecimiento bacteriano. El objetivo del tratamiento es mejorar la exagerada acidez vaginal para lo cual se recomienda el empleo de baños de asiento o duchas vaginales con bicarbonato de sodio entre otras medidas. Conclusiones: La VC es una entidad frecuente pero poco conocida, comúnmente confundida con VVC. Su tratamiento debe evitar el uso de antimicóticos.

Prevalence of potentially pathogenic microbiological agents in vaginal exudates of asymptomatic pregnant women, barranquilla, colombia, 2014-2015 / Prevalencia de agentes microbiológicos potencialmente patógenos en el exudado vaginal de gestantes asintomáticas, barranquilla, colombia, 2014-2015

ABSTRACT Objective: To determine the prevalence of potentially pathogenic microbiological agents in vaginal exudates in a sample of asymptomatic pregnant women in the Department of Atlantico, Colombia. Materials and Methods: Descriptive cross-sectional study of a sample of asymptomatic pregnant women who attended a private primary healthcare institution in Barranquilla, Colombia, between 2014 and 2015. Pregnant women having received antimicrobial treatment within the last 30 days, with vaginal bleeding, mental disability or immunosuppression, were excluded. Consecutive sampling was performed. The prevalence of colonization time by some of the microbiological agents as well as specific prevalence were estimated: number of women with infection by agent type/number of women at risk assessed. Results: Overall prevalence was 24.8% (56/226); 55.4% (31/56) was due to vaginitis causal agents, and 44.6% (25/56) to vaginosis. The specific prevalence by type of pathogen, 13.3% (30/226) was vaginitis due to colonization by Candida spp. and 0.4% (1/226) was vaginitis due to T. vaginalis. Bacterial vaginosis (BV) was found in 8.0% (18/226). Conclusion: Substantial colonization of the lower genital tract by potentially pathogenic germs is found in pregnant women between 35 and 37 weeks of gestation. Further studies are required in order to determine the benefit of population screening in terms of avoiding poor maternal and perinatal outcomes, and the impact on the resulting overcosts.

RESUMEN Objetivo: establecer la prevalencia de agentes microbiológicos potencialmente patógenos en el exudado vaginal de gestantes asintomáticas del departamento del Atlántico, Colombia. Materiales y métodos: estudio de corte transversal descriptivo. Se incluyeron gestantes asintomáticas que acudieron a una institución privada de atención primaria en salud en Barranquilla, Colombia, en 2014 y 2015. Se excluyeron gestantes con tratamiento antimicrobiano en los últimos 30 días, sangrado genital, discapacidad mental e inmunosupresión. Se hizo un muestreo consecutivo no estricto. Se calculó la prevalencia de periodo de colonización por algunos de los agentes microbiológicos y la específica: número de mujeres con infección por tipo de agente/número de mujeres evaluadas en riesgo. Resultados: la prevalencia global fue de 24,8 % (56/226). De estas, el 55,4 % (31/56) fue debido a vaginitis y el 44,6 % (25/56) por vaginosis. La prevalencia específica según tipo de patógenos fue: vaginitis por Candida spp. en 13,3 % (30/226) y por T. vaginalis 0,4 % (1/226). La VB se presentó en 8,0 % (18/226) y una flora intermedia de 3,1 % (7/226). Conclusión: existe una importante colonización del tracto genital inferior de gérmenes potencialmente patógenos en mujeres gestantes de 35 a 37 semanas. Se requieren estudios adicionales para determinar el beneficio de la tamización poblacional en términos de malos resultados maternos perinatales evitados y costos.

Systematic review: The potency of Zataria multiflora Boiss in treatment of vaginal infections / Revisión sistemática: Potencia de la calendula Zataria multiflora para el tratamiento de infecciones vaginales

Vaginitis as female infectious disease is accompanied with some clinical symptoms such as vaginal abnormal discharges, itching, burning and many other unpleasant signs in patients. The responsible microorganisms in vaginitis are belonged to different kind of microorganisms including bacteria (Gardenella vaginitis), yeast (Candida albicans) and protozoa (Trichomonas vaginalis). The current treatments of these infections are chemical oral and vaginal drugs with many adverse effects for patients. Furthermore, appearance of resistant microorganisms to these drugs has intensified the treatment's problem. The aim of this review article was to evaluate the potency of "Zataria multiflora" essential oil in treatment of women's vaginitis. For preparing this manuscript, the information was extracted from different electronic and published resources. Investigation in different resources showed there were 6 clinical trials that evaluate it as suitable treatment for vaginitis. 5 clinical studies have been focused on 0.1% Z. multiflora essential oils in treatment of bacterial vaginosis (n=1), candidiasis (n=1) and trichomoniasis (n=1). Two clinical studies were related to treatments of bacterial vaginosis, trichomoniasis and mixed infection. There is one clinical study for treatment of candidiasis by 1% Z. multiflora methanol extract. Z. multiflora was formulated in cream form and applied for 5-7 continuous days. The results of clinical trials showed that Z. multiflora essential oil (0.1%) can be used as safe and efficient alternative treatment for treatment of bacterial vaginosis, candidiasis and to a lesser extent for trichomoniasis.

La vaginitis es una enfermedad infecciosa femenina acompañada de algunos síntomas como flujo vaginal, prurito, sensación de ardor y otros síntomas de incomodidad para las pacientes. Los microorganismos responsables de vaginitis son variados e incluyen bacterias (Gardenella vaginitis), hongos (Candida albicans) y protozoos (Trichomonas vaginalis). Los tratamientos utilizados actualmente son medicamentos de uso oral o vaginal con potenciales efectos adversos. Adicionalmente se encuentran organismos resistentes a estos tratamientos, lo que ha llevado a la búsqueda de nuevas alternativas. El propósito de esta revisión sistemática fue evaluar la potencia del aceite esencia de "Zataria multiflora" para el tratamientos de la vaginitis. Se realizó una búsqueda en recursos bibliográficos y bases de datos electrónicos. Se encontraron seis ensayos clínicos que evaluaron este aceite para el tratamiento de la vaginitis. En 5 estudios clínicos se utilizó aceite esencial al 0.1% de Z. multiflora para el tratamiento de vaginosis bacteriana (n=1), candidiasis (n=1) y tricomoniasis (n=1) y en tres estudios se usó para tratamiento tanto de infecciones bacterianas, tricomoniasisi o mixtas. Se encontró un estudio para tratamiento de la candidiasis con extracto en metanol 1% de Z. multiflora. Se hizo formulación de Z. multiflora en crema tópica y aplicada por 5-7 días continuos. Los resultados mostraron que el aceite esencial de Z. multiflora (0.1%) puede ser usado de manera segura y eficiente como alternativa en vaginosis bacteriana, candidiasis y en menor grado para tricomoniasis.

Frequência sazonal de vaginose bacteriana e Candida sp em esfregaços citológicos de laboratório privado na cidade de Fortaleza entre 2012 e 2015 / Sazonal frequency of Bacterial vaginosis and Candida sp in Pap smears observed in a private laboratory in Fortaleza, Brazil, from 2012 to 2015

As mais frequentes queixas ginecológicas estão associadas a infecções genitais, que afetam a microbiota vaginal, ou seja, vaginites e vaginoses. A vaginose bacteriana (VB) é caracterizada por uma mudança da microbiota vaginal de bactérias aeróbias para anaeróbias. Já a candidíase vulvovaginal (CVV) é um distúrbio ocasionado pelo crescimento anormal de fungos do tipo leveduras na mucosa do trato genital feminino. Objetivo: Identificar a frequência de VB e Candida sp em exames citológicos (Papanicolaou) em uma cidade no nordeste do Brasil, conforme os meses do ano em um período de quatro anos. Métodos: Estudo de frequência da identificação de VB e Candida sp em exames de citologia oncótica do banco de dados do Laboratório Professor Eleutério em Fortaleza entre os anos de 2012 e 2015. Resultados: Os casos avaliados tinham entre 14 e 54 anos, média de 34,7 anos. Em 2012, o mês de agosto teve maior frequência de VB (62,96%), e o mês de março teve a maior frequência de Candida sp (42,35%). No ano de 2013, VB foi mais prevalente em setembro (61,98%) e Candida sp em agosto (47,26%). Já em 2014, o mês de junho teve maior frequência VB (60,47%), e setembro maior frequência de Candida sp (43,30%). Em 2015, foi abril o mês em que mais se detectou VB (60,30%) e em junho, Candida sp (41,85%). Conclusão: A frequência de VB foi maior que a de Candida sp nos quatro anos. Os meses com maior frequência de patógenos identificados foram os de junho, agosto e setembro, no entanto não houve grandes modificações entre a distribuição durante todo o ano.

The most frequent gynecological complaints are associated with genital infections, which affect the vaginal microbiota, i.e., vaginitis and vaginosis. Bacterial vaginosis (BV) is characterized by a change of the vaginal microbiota from aerobic bacteria to anaerobic bacteria. Vulvovaginal candidiasis (VVC) is a disorder caused by the abnormal growth of yeast type fungi in the mucosa of the female genital tract. Objective: To identify the frequency of BV and Candida sp in Pap (Papanicolaou) smears in a city of Northeastern Brazil, according to the months of the year for a period of four years. Methods: Study of the frequency of the identification of BV and Candida sp in the oncotic cytology tests carried out in the Professor Eleutério Laboratory database in the city of Fortaleza from 2012 to 2015. Results: The average age of the evaluated cases was 34.7 years, varying from 14 to 54 years of age. In 2012, August was the month with a higher frequency of BV (62.96%), and the month of March had the highest frequency of Candida sp (42.35%). In 2013, BV was more prevalent in September (61.98%) and Candida sp in August (47.26%). In 2014, however, the month of June showed most often BV (60.47%) and September had a higher frequency of Candida sp (43.30%). In 2015, it was April the month in which BV was most detected (60.30%), and in June, Candida sp (41.85%). Conclusion: The frequency of bacterial vaginosis was higher than that of Candida sp during four years. The months with the highest frequency of identified pathogens were June, August and September; however, there were no major changes throughout the year.

Analysis of the Vaginal Microbiome by Next-Generation Sequencing and Evaluation of its Performance as a Clinical Diagnostic Tool in Vaginitis

BACKGROUND: Next-generation sequencing (NGS) can detect many more microorganisms of a microbiome than traditional methods. This study aimed to analyze the vaginal microbiomes of Korean women by using NGS that included bacteria and other microorganisms. The NGS results were compared with the results of other assays, and NGS was evaluated for its feasibility for predicting vaginitis. METHODS: In total, 89 vaginal swab specimens were collected. Microscopic examinations of Gram staining and microbiological cultures were conducted on 67 specimens. NGS was performed with GS junior system on all of the vaginal specimens for the 16S rRNA, internal transcribed spacer (ITS), and Tvk genes to detect bacteria, fungi, and Trichomonas vaginalis. In addition, DNA probe assays of the Candida spp., Gardnerella vaginalis, and Trichomonas vaginalis were performed. Various predictors of diversity that were obtained from the NGS data were analyzed to predict vaginitis. RESULTS: ITS sequences were obtained in most of the specimens (56.2%). The compositions of the intermediate and vaginitis Nugent score groups were similar to each other but differed from the composition of the normal score group. The fraction of the Lactobacillus spp. showed the highest area under the curve value (0.8559) in ROC curve analysis. The NGS and DNA probe assay results showed good agreement (range, 86.2-89.7%). CONCLUSIONS: Fungi as well as bacteria should be considered for the investigation of vaginal microbiome. The intermediate and vaginitis Nugent score groups were indistinguishable in NGS. NGS is a promising diagnostic tool of the vaginal microbiome and vaginitis, although some problems need to be resolved.

Randomized, single-blinded comparison of efficacy, safety and tolerability of metronidazole 750mg - miconazole 200mg vaginal suppository vs. metronidazole 500mg - nystatin 100, 000 IU vaginal suppository in the treatment of bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis, and mixed vaginal infections / Philippine Journal of Obstetrics and Gynecology

OBJECTIVE: This randomized, single-blind, two-arm controlled study compared the efficacy, safety, and tolerability of an intravaginal suppository preparation containing metronidazole 750mg + miconazole 200mg (Neopenotran Forte) with another vaginal preparation containing metronidazole 500 mg + nystatin 10000 IU (Flagystatin) in the treatment of bacterial vaginosis (BV), candidal and trichomonial vulvovaginitis (CVV, TV), mixed vaginitis and in the prevention of secondary candidal vulvovaginitis. MATERIALS AND METHODS: Women ages 18-45 years with chief complaints of abnormal vaginal discharge or vaginal/vulvar itching were examined and microbiologic confirmation of BV, VVC, TV or mixed infection was made. They were then randomly assigned to receive either treatment once daily (nightly) for 7 days. A total of 261 subjects had evaluable clinical and microbiological findings at the end of the study. Test of cure by Amsel criteria and Nugent score were performed twice after treatment. RESULTS: The overall test revealed that microbiological cure rate is significantly different between the two treatment groups. CONCLUSION: The odds of being cured microbiologically is 2.35 times more in the metronidazole 750mg + miconazole nitrate 200mg group compared to the metronidazole 500 mg + nystatin 10000 IU group. However, no significant difference in the clinical cure between the two groups was found. Both drugs are safe and convenient to use.

Clinical observation on treatment of mycotic vaginitis with Sophora gel combined with Fluconazole capsules / 中国中药杂志

Mycotic vaginitis is a common and frequently-occurring gynaecopathia and easy to attack repeatedly, so painful to patients. In this study, the authors observed the clinical efficacy of Sophora gel combined with Fluconazole capsules in treating mycotic vaginitis, in order to seek an effective method for treating mycotic vaginitis. Totally 85 patients with mycotic vaginitis treated in our hospital between December 2012 and July 2014 were randomly divided into the treatment group (43 patients) and the control group (42 patients). The treatment group was given vaginally Sophora gel (one piece every night for 14 days) and orally Fluconazole capsules (150 mg, once every three days, four times in total); The control group was only administered with Fluconazole capsules. The total efficacy, cure rate, recurrence rate and clinical symptom improvements of the two groups were observed. The results show that the total efficacy, the cure rate and the recurrence rate of the treatment group vs. the control group were respectively 97.7%, 90.7% and 2.6% vs. 83.3%, 71.4% and 20.0%, with statistical significance in their differences (P < 0.05). The treatment group showed reduced leucorrhea, pruritus vulvae disappearance and earlier mucosal hyperemia disappearance than the control group, with statistical significance in their differences (P < 0.05). In conclusion Sophora gel combined with Fluconazole capsules can improve antifungal activity of drugs, relieve clinical symptoms, shorten the course of disease, enhance the cure rate and reduce the recurrence rate; So this therapy can be widely applied in clinic.

An Open, Comparative, Randomized, Parallel, Post Marketing, Multicentric Trial to Compare the Safety and Efficacy of Formula A (Ofloxacin + Ornidazole + Terbinafine Hydrochloride + Clobetasol Propionate) versus Formula B (Clotrimazole + Beclometasone Dipropionate + Neomycin Sulphate), Formula C (Clotrimazole + Beclometasone Dipropionate + Neomycin Sulphate) and Formula D (Clotrimazole + Beclometasone Dipropionate + Neomycin Sulphate) in the Treatment of Patients with Vaginitis.

Vaginitis is among the most common conditions for which women seek medical care, with vaginal discharge accounting for approximately 10 million office visits each year. Since there are no published studies till date that evaluated the Clinical Effectiveness and Safety of Topical Cream of Formula A [Ofloxacin (0.75 % w/w) + Ornidazole (2% w/w) + Terbinafine Hydrochloride (1% w/w) + Clobetasol Propionate (0.05% w/w)] compared to Formula B [Clotrimazole (1%w/w) + Beclometasone Dipropionate (0.025%w/w) + Neomycin Sulphate (0.5% w/w)], Formula C [Clotrimazole (1%w/w) + Beclometasone Dipropionate (0.025%w/w) + Neomycin Sulphate (0.5% w/w)], and Formula D [Clotrimazole (1%w/w) + Beclometasone Dipropionate (0.025%w/w) + Neomycin Sulphate (0.5% w/w)], in mild to moderate vaginitis, hence we undertook this randomized controlled Post Marketing Multicentric trial. Materials and methods: Female subjects diagnosed with mild to moderate symptoms of Vaginitis were eligible and those fulfilling the subject selection criteria were randomized to receive either Formula A, Formula B, Formula C or Formula D for 14 days. The Primary efficacy measures were assessment of symptoms of Vaginitis i.e. vaginal pruritis, vaginal irritation, vaginal soreness or pain, dyspareunia, vaginal erosion and vaginal inflammation and Secondary efficacy measures were assessment of Physical characteristics of vaginal discharge, assessment of pH of vaginal discharge and Microbiological evaluation. Assessment of Safety was done by recording the occurrence of adverse drug reactions. Results: The clinical success rates were comparable and even far better in case of Formula A group (in vaginal pain, Dyspareunia and vaginal erosion it was 100 %, in case of vaginal inflammation it was 92.655 % while in case of vaginal irritation, it was 94.767 % and vaginal pruritus, it was 87.096 %). Adverse events were mild and self limiting while it was totally absent in case of Formula A group. Conclusion: Topical Cream of Formula A is safe and effective for the treatment of mild to moderate vaginitis.

Influence of human papillomavirus infection on the vaginal microbiome of women with immunocompetency / Influência da infecção por papillomavirus humano no microbioma vaginal de mulheres imunocompetentes

The influence of vaginal infections on the natural history of human papillomavirus (HPV) is still unclear. Objective: To determine if patientswith low-grade squamous intraepithelial lesions (LSILs) and HPV have more vulvovaginitis than patients with normal liquid-based cervical cytology whowere negative for HPV. Methods: This is a cross-sectional study including 322 patients who underwent cervical exams. One hundred and sixty-seven ofthese patients had LSILs on cervical cytology and were simultaneously hybrid capture 2 (HC2)-positive for HPV, and the remaining 155 patients were negative for malignancies and intraepithelial lesions by cytology and HC2-negative for HPV. The prevalence of vaginal infections in both groups was compared using the X2 test without Yates' correction. Results: Among the patients with HPV and LSILs, the most common vaginal infection was vaginosis(8.98%) compared to candidiasis (12.9%) in the patients without LSILs and HPV. No significant differences were found in the prevalence of vaginosisbetween the two groups (p=0.53). Candidiasis was statistically more prevalent in patients without LSILs and HPV (p<0.001). Conclusion: An associationwas found between the presence of Candida and the absence of HPV. Although vaginosis was more frequent among patients with LSILs and HPV, it wasnot statistically significant.

A influência das infecções vaginais na história natural do papillomavirus humano (HPV) ainda é incerta. Objetivo: Determinar se pacientes com lesões intraepiteliais escamosas de baixo grau (LIEBG) e HPV têm mais vulvovaginites que aquelas com citologia cervical em meio líquido normal e testes negativos para HPV. Métodos: Este é um estudo transversal, que incluiu 322 mulheres que fizeram exames de colo. Cento e sessenta e sete destas tinham LIEBG na citologia oncótica e foram simultaneamente positivas para HPV na captura híbrida 2 (CH2). As outras 155 tiveram citologias negativas para neoplasia intraepitelial e malignidade e eram CH2 negativas para HPV. A prevalência de infecção vaginal nos dois grupos foi comparada usando o teste do X2 sem correção de Yates. Resultados: Entre as pacientes com HPV e LIEBG, a infecção vaginal mais comum foi a vaginose (8,98%), enquantoque, no grupo sem LIEBG e sem HPV, foi a candidíase (12,9%). Nenhuma diferença estatisticamente significante foi encontrada na prevalência de vaginose entre os dois grupos (p=0,53). Candidíase foi estatisticamente mais prevalente nas pacientes sem LIEBG e HPV (p<0,001). Conclusão: Foi encontrada uma associação entre a presença de Candida e a ausência de HPV. Embora a vaginose tenha sido mais frequente em pacientes com LIEBG e HPV, esse dado não foi estatisticamente significante.

Interpretation of Papanicolaou Smear Test and Gram Stain Results for the Diagnosis of Infectious Vaginitis is Affected by Knowledge of Additional Related Test Results

BACKGROUND: Infectious vaginitis is a common gynecologic disease that is primarily caused by three pathogens (Trichomonas vaginalis, Gardnerella vaginalis, and Candida species). The aim of this study was to confirm the effects of other infectious vaginitis-related test results on the interpretation of Gram stain and Papanicolaou (Pap) smear test results for disease diagnosis. METHODS: A total of 300 vaginal samples were collected from women presenting symptoms of vaginitis. The presence of the three previously mentioned pathogens was evaluated using both a Gram stain and Pap smear test, and interpreted twice by 4 different observers. The first interpretation was performed without any information, and a second interpretation was performed with knowledge of results of an Affirm VPIII test that was used to diagnose infectious vaginitis. The results from the two interpretations were compared and the sensitivity and specificity of both tests were evaluated. RESULTS: For the Gram stain samples, the detection rates of G. vaginalis were increased in the second interpretation by 6.2%, while the detection rates of Candida spp. were decreased by 0.3%. For the Pap smear test samples, the detection rates of G. vaginalis were increased in the second interpretation by 7.0%, and the detection rates of Candida spp. were increased by 2.0%. The sensitivity of both tests was increased in the second interpretation by 5.5% to 66.7%. There was no difference in the specificity between the two interpretations. CONCLUSIONS: We demonstrated that there is significant inter-observer variation when using Gram stain and Pap smear test results to diagnose infectious vaginitis. The detection rates and sensitivity of both tests changed when the results from an additional test were incorporated into the interpretation. Additional studies are needed to develop objective criteria and a standardized interpretation system for the evaluation of results from these diagnostic tests.